Association Between Initial Opioid Prescribing Patterns and Subsequent Long-Term Use Among Opioid-Naïve Patients: A Statewide Retrospective Cohort Study

Journal of General Internal Medicine

Volumn 32, Issue 1, 2017, Pages 21-27

  Deyo, Richard A ^a,b   Hallvik, Sara E ^c   Hildebran, Christi ^c   Marino, Miguel ^a,b   Dexter, Eve ^a   Irvine, Jessica M ^c,d   O’Kane, Nicole ^c   Van Otterloo, Joshua ^e   Wright, Dagan A ^e   Leichtling, Gillian ^c   Millet, Lisa M ^e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Acumentra Health   (United States)

^d OCHIN Inc   (United States)

^e Injury and Violence Prevention Section Oregon Health Authority   (United States)

Author keywords

opioid initiation; opioid na ve; opioids; pain; prescription drug monitoring programs

Indexed keywords

ANTITUSSIVE AGENT; CODEINE; HYDROCODONE; LONG ACTING DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; SHORT ACTING ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ANALGESIA; ARTICLE; CHILD; DRUG USE; HIGH RISK PATIENT; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; NEWBORN; OREGON; PRESCRIPTION; RETROSPECTIVE STUDY; CHI SQUARE DISTRIBUTION; CHRONIC PAIN; CLINICAL PRACTICE; DOSE RESPONSE; OPIATE ADDICTION; PRESCHOOL CHILD; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHRONIC PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; OPIOID-RELATED DISORDERS; OREGON; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84982853972     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-016-3810-3     Document Type: Article

References (40)

1. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981–5.
2. Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs: overdoses of prescription opioid pain relievers, United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60:1487–92.
3. Juurlink DN, Dhalla IA, Nelson LS. Improving opioid prescribing: the New York City recommendations. JAMA. 2013;309:879–80.
4. Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann Intern Med. 2011;155:325–8.
5. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573–82.
6. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569–76.
7. Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart WF. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction. 2010;105:1776–82.
8. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention workshop. Ann Intern Med. 2015;162:276–86.
9. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24:469–78.
10. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD.. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30:557–64.
11. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–21.
12. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.
13. Gomes T, MaMD.ani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171:686–91.
14. Oregon Health Authority, Center for Prevention & Health Promotion, Injury & Violence Prevention Section. 2014 Drug overdose deaths, hospitalizations, abuse & dependency among Oregonians. Available at: https://public.health.oregon.gov/DiseasesConditions/InjuryFatalityData/Documents/oregon-drug-overdose-report.pdf. Accessed 24 June 2016.
15. Deyo RA, Irvine JM, Millet LM, Beran T, O’Kane N, Wright DA, McCarty D. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions. Health Aff. 2013;32:603–13.
16. Deyo RA, Irvine JM, Hallvik SE, Hildebran C, Beran T, Millet LM, Marino M. Leading a horse to water: facilitating registration and use of a prescription drug monitoring program. Clin J Pain. 2015;31:782–7.
17. Campbell KM, Deck D, Krupski A. Record linkage software in the public domain: a comparison of Link Plus, The Link King, and a ‘basic’ deterministic algorithm. Health Informatics J. 2008;14:5–15.
18. Beil H, Preisser JS, Rozier RG. Accuracy of record linkage software in merging dental administrative data sets. J Public Health Dent. 2013;73:89–93.
19. US Food and Drug Administration. National Drug Code Database File. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm. Accessed 24 June 2016.
20. National Center for Injury Prevention and Control. CDC Conversion Reference Table. A compilation of opioid analgesic formulations with morphine milligram equivalent conversion factors, 2014 version. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www.pdmpassist.org/pdf/BJA_performance_measure_aid_MME_conversion.pdf. Accessed Conversion Reference Table.xlsx June 24, 2016.
21. O’Kane N, Hallvik SE, Marino M, Van Otterloo J, Hildebran C, Leichtling G, Deyo RA. Preparing a prescription drug monitoring program data set for research purposes. Pharmacoepidemiol Drug Saf. 2016. doi:10.1002/pds.4039.
22. Centers for Disease Control. CDC Wonder, United States Cancer Statistics, 1999–2012, Cancer Incidence 2012 – Invasive Cancers. Available at: http://wonder.cdc.gov/cancer-v2012.html. Accessed 24 June 2016.
23. National Hospice and Palliative Care Organization. NHPCO’s Facts and Figures: Hospice Care in America, 2014 Edition. Available at: http://www.nhpco.org/sites/default/files/public/Statistics_Research/2014_Facts_Figures.pdf. Accessed 24 June 2016.
24. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA. 2016;315:1624–45.
25. Morden NE, Munson JC, Colla CH, Skinner JS, Bynum JPW, Zhou W, Meara E. Prescription opioid use among disabled Medicare beneficiaries: intensity, trends, and regional variation. Med Care. 2014;52:852–9.
26. Cochran WG. Some methods for strengthening the common chi-squared tests. Biometrics. 1954;10:417–51.
27. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375–86.
28. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med. 2014;174:796–801.
29. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012;13:87–95.
30. Hooten WM, St. Sauver JL, McGree ME, Jacobson DJ, Warner DO. Incidence and risk factors for progression from short-term to episodic or long-term opioid prescribing: a population-based study. Mayo Clin Proc. 2015;90:850–6.
31. Weisner CM, Campbell CI, Ray GT, et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain. 2009;145:287–93.
32. Braden JB, Sullivan MD., Ray GT, et al. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry. 2009;31:564–70.
33. Edlund MJ, Martin BC, Devries A, Ming-Yu F, Braden JB, Sullivan MD.. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010;26:1–8.
34. Sullivan MD., Howe CQ. Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013;154(Suppl 1):S94–100.
35. Mistry CJ, Bawor M, Desai D, Marsh DC, Samaan Z. Genetics of opioid dependence: a review of the genetic contribution to opioid dependence. Curr Psychiatr Rev. 2014;10:156–67.
36. Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H, Farrer LA. Genome-Wide Association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry. 2014;76:66–74.
37. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.
38. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, Chou R. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160:38–47.
39. Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175:608–15.
40. Dowell D, Kunins HV, Farley TA. Opioid analgesics – risky drugs, not risky patients. JAMA. 2013;309:2219–20.